Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Contract symbols : EBS save search
Emergent BioSolutions Awarded Procurement Contract Valued up to $235.8 Million to Supply BioThrax® (Anthrax Vaccine Adsorbed) to the U.S. Department of Defense
Published: 2024-01-11 (Crawled : 13:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 3.69%
H: 0.0%
C: -6.67%
biothrax defense vaccine contract million
Emergent BioSolutions Receives $75 Million Contract Option from BARDA to Procure Doses of CYFENDUS™ (Anthrax Vaccine Adsorbed, Adjuvanted)
Published: 2023-11-28 (Crawled : 12:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 2.42%
H: 1.42%
C: -5.19%
vaccine contract
Emergent BioSolutions Awarded 10-Year BARDA Contract Valued at up to a Maximum of $704 Million for Advanced Development and Procurement of Ebanga™ Treatment for Ebola
Published: 2023-07-31 (Crawled : 20:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 6.83%
H: 11.7%
C: 7.62%
ebola contract treatment
Emergent BioSolutions Awarded $379.6 Million Procurement Contract to Supply RSDL© (Reactive Skin Decontamination Lotion Kit) to U.S. Department of Defense
Published: 2023-01-05 (Crawled : 23:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 3.72%
H: 8.04%
C: 5.85%
defense contract skin
Chimerix Awarded BARDA Contract for TEMBEXA as Medical Countermeasure for Smallpox
Published: 2022-08-29 (Crawled : 15:00) - globenewswire.com
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -2.07%
H: 2.67%
C: -1.91%
CMRX | $0.8844 -5.14% -5.42% 430K
|
Health Technology
|
| O: -0.93%
H: 25.23%
C: 8.88%
smallpox tembexa contract
Emergent BioSolutions On Track with Respect to COVID-19 Contractual Commitments; Receives Modified Task Order from the U.S. Department of Health & Human Services to Support the Opportunity for Further Expansion of Manufacturing Capacity for Johnson & Johnson’s COVID-19 Vaccine
Published: 2021-04-05 (Crawled : 03:00) - globenewswire.com
JNJ | News | $147.91 1.49% -0.03% 9.6M
|
Health Technology
|
| O: 0.5%
H: 0.68%
C: -0.13%
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: -0.53%
H: 0.11%
C: -1.76%
covid expansion contract vaccine merge order
Humanigen and Emergent BioSolutions Announce Contract Development and Manufacturing Agreement for Phase 3 COVID-19 Therapeutic Candidate Lenzilumab™
Published: 2021-01-25 (Crawled : 18:00) - biospace.com/
EBS | $2.04 9.68% 0.49% 930K
|
Health Technology
|
| O: 0.0%
H: 0.0%
C: -0.7%
HGEN | $0.0361 -61.5% 120M
|
Health Technology
|
| O: 0.71%
H: 1.32%
C: -2.74%
covid contract phase 3 merge lenzilumab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.